The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial
Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF
Journal of hypertension · 74 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2009-08-19 · J Hypertens · vol. 27 · número 9 · págs. 1863–1872
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 99 citas · más que el 96% de estudios similares · 6.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 41 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Coenzyme Q10 studies and effects · Blood Pressure and Hypertension Studies
- Palabras clave
- omega-3 fatty acids, coenzyme Q10, chronic kidney disease, blood pressure, heart rate, ambulatory blood pressure, triglycerides, cardiovascular risk, dietary supplements, non-diabetic patients
- MeSH
- arteries, blood platelets, humans, albuminuria, hypertension, ubiquinone, insulin, blood glucose, fatty acids, omega-3, fatty acids, phospholipids, echocardiography, diet, double-blind method, life style, blood pressure, heart rate, drug synergism, adult, aged, middle aged, female, male, dyslipidemias, renal insufficiency, chronic
8 autores
- Trevor Anthony Mori🇦🇺 · autor de correspondenciaThe University of Western Australia; Royal Perth Hospital
- Valerie Burke🇦🇺The University of Western Australia; Royal Perth Hospital
- Ian B. Puddey🇦🇺The University of Western Australia; Royal Perth Hospital
- Ashley Bruce Irish🇦🇺Royal Perth Hospital
- Christine A Cowpland🇦🇺The University of Western Australia; Royal Perth Hospital
- Lawrence Joseph Beilin🇦🇺The University of Western Australia; Royal Perth Hospital
- Gursharan K. Dogra🇦🇺The University of Western Australia; Royal Perth Hospital
- Gerald F. Watts🇦🇺The University of Western Australia; Royal Perth Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and objective
Chronic kidney disease (CKD) associates with increased cardiovascular disease (CVD) risk. Hypertension is a major determinant of progression of CKD. Omega-3 fatty acids (omger3FA) protect against CVD via improvements in blood pressure, heart rate, vascular reactivity and serum lipids. Coenzyme Q(10) (CoQ) may improve blood pressure and vascular function. This study determined whether omega3FA and CoQ have independent or additive effects in improving the cardiovascular profile, particularly blood pressure and heart rate, in nondiabetic patients with CKD stages 3-4.
Methods
In a double-blind, placebo-controlled intervention, patients were randomized to either omega3FA (4 g), CoQ (200 mg), both supplements or control (4 g), daily for 8 weeks.
Results
Eighty-five patients aged 56.5 +/- 1.4 years; BMI 27.3 +/- 0.5 kg/m(2); supine blood pressure 125.0/72.3mmHg; and glomerular filtration rate 35.8 +/- 1.2 ml/min/1.73m(2), were randomized. Seventy-four completed the study. omega3FA, but not CoQ, reduced 24-h ambulatory heart rate (P<0.0001) and blood pressure (P<0.0001). Main effects for omega3FA on 24-h measurements were -3.3 +/- 0.7/ -2.9 +/- 0.5mmHg and -4.0 +/- 0.5 bpm. Postintervention blood pressure showed significant interactions between treatments. omega3FA reduced triglycerides 24% (P<0.001). There were no changes in glomerular filtration rate, urinary albumin or total protein excretion, cholesterol, HDL-cholesterol (C), LDL-C, glucose, insulin, or high-sensitivity C-reactive protein.
Conclusion
This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD. CoQ had no independent effect on blood pressure but increased heart rate. These results show that omega3FA lower blood pressure and may reduce cardiovascular risk in nondiabetic patients with moderate-to-severe CKD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.